Table 1.
Summary of GLM trials.
| Trial (Clinical Trial Identifier Number) | Official Title | Study Type (Phase) | Indication | Number of Participants |
|---|---|---|---|---|
| GO-BEFORE (NCT00264537) | A multicentre, randomized, double-blind, placebo-controlled trial of golimumab, a fully human anti-TNFa monoclonal antibody, administered subcutaneously, in methotrexate-naïve subjects with active rheumatoid arthritis | Clinical Trial (Phase III) | RA | 637 |
| GO-FORWARD (NCT00264550) | A multicentre, randomized, double-blind, placebo-controlled trial of golimumab, a fully human anti-TNFa monoclonal antibody, administered subcutaneously, in subjects with active Rheumatoid arthritis despite methotrexate therapy | Clinical trial (Phase III) | RA | 444 |
| GO-AFTER (NCT00299546) | A multicentre, randomized, double-blind, placebo-controlled trial of golimumab, a fully human anti-TNFa monoclonal antibody, administered subcutaneously in subjects with active rheumatoid arthritis and previously treated with biologic anti-TNFa Agent(s) | Clinical trial (Phase III) | RA | 461 |
| GO-MORE (NCT00975130) | An open-label study assessing the addition of subcutaneous golimumab (GLM) to conventional disease-modifying antirheumatic drug (DMARD therapy in biologic-naïve subjects with rheumatoid arthritis (Part 1), followed by a randomized study assessing the value of combined intravenous and subcutaneous GLM administration aimed at inducing and maintaining remission (Part 2) | Clinical trial (Phase III) | RA | 3366 |
| GO-FURTHER (NCT00973479 | A multicentre, randomized, double-blind, placebo-controlled trial of golimumab, an anti-TNF alpha monoclonal antibody, administered intravenously, in patients with active rheumatoid arthritis despite methotrexate therapy | Clinical trial (Phase III) | RA | 592 |
| GO-NICE (NCT01313858) | Non-interventional study investigating the use of golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis | Observational | RA, PsA, AS | 1613 |
GLM: golimumab; TNF: tumor necrosis fator; RA: rheumatoid arthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; nr-AxSpA: non-radiographic axial spondyloarthritis.